Every Form 4 that ENDRA Life Sciences Inc. (NDRA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NDRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NDRA filings page.
ENDRA Life Sciences reported that Chief Executive Officer Alexander Y. Tokman acquired 26,921 shares of common stock through a grant of restricted stock units (RSUs) at a price of $0.00 per share. These RSUs convert to common stock on a one-for-one basis and will vest in full on June 11, 2026. Following this award, Tokman directly holds 101,926 shares of common stock, and the holdings disclosure notes that this amount includes unvested RSUs.
ENDRA Life Sciences Inc. reported that its Chief Financial Officer, Richard Jacroux, received a grant of 13,461 shares of common stock as a stock award. The shares, structured as restricted stock units that convert one-for-one into common stock, will vest in full on June 11, 2026. Following this award, Jacroux holds 33,461 shares of common stock, including unvested restricted stock units.
ENDRA Life Sciences Inc. director Anthony DiGiandomenico reported a stock-based award of the company’s common stock. On January 21, 2026, he acquired 60,324 shares at a price of $0, representing restricted stock units (RSUs) that convert to common stock on a one-for-one basis. These RSUs will vest in full on January 21, 2027, meaning he will receive the underlying shares on that date if vesting conditions are met. After this grant, he beneficially owns 136,589 shares of ENDRA common stock, held directly, which includes unvested RSUs.
ENDRA Life Sciences director Michael Harsh reported an equity award of 60,324 shares on January 21, 2026. The filing shows these are restricted stock units (RSUs) that convert into common stock on a one-for-one basis and will vest in full on January 21, 2026. The transaction was recorded at a price of $0 per share, indicating a compensatory grant rather than an open-market purchase. Following this award, Harsh beneficially owned 65,710 shares of common stock, and his holdings include unvested RSUs.
ENDRA Life Sciences Inc. reported that its Chief Financial Officer, Richard Jacroux, acquired 20,000 shares of common stock on January 21, 2026. The shares come from restricted stock units that were granted at a price of $0 per share and convert into common stock on a one-for-one basis. After this transaction, he beneficially owns 20,000 common shares directly. The RSUs are scheduled to vest in full on January 21, 2027, meaning the CFO will receive all underlying shares on that date if vesting conditions are met.
ENDRA Life Sciences director Lou Basenese received a stock-based award from the company. On January 21, 2026, he was granted 60,324 shares of common stock in the form of restricted stock units (RSUs) at a grant price of $0 per share. Each RSU converts into one share of common stock.
The RSUs will vest in full on January 21, 2027, meaning they convert to common shares on that date if vesting conditions are met. After this grant, Basenese beneficially owned a total of 65,709 shares of ENDRA Life Sciences common stock, which the disclosure notes includes unvested RSUs, all held directly.
ENDRA Life Sciences Chief Executive Officer and Director Alexander Y. Tokman received 75,000 shares of common stock on January 21, 2026 as an equity award. These shares represent restricted stock units that convert into common stock on a one-for-one basis and will vest in full on January 21, 2027. Following this grant, Tokman beneficially owned 75,005 shares of ENDRA Life Sciences common stock directly.
ENDRA Life Sciences (NDRA) reported an insider purchase by director Anthony DiGiandomenico on 10/10/2025. He acquired 70,822 shares of common stock at $7.06 and 141,644 warrants with a $6.81 exercise price in a private placement exempt under Rule 16b-3(d)(1). Following the transaction, he beneficially owned 76,265 shares, which includes unvested RSUs. The warrants become exercisable on 10/15/2025 and expire on 10/15/2030. Ownership is reported as direct.